Mary Cushman: Unprovoked VTE as a Marker of Increased Cardiovascular Mortality Risk
Mary Cushman, University Distinguished Professor and Vice Chair at the University of Vermont, shared Debora Kamin Mukaz‘s post on LinkedIn, adding:
“Alert! People with unprovoked VTE have double the risk of death than those without VTE.
Their leading cause of death is circulatory disease.
When you are seeing patients with VTE think big picture.
Start a statin if indicated.
Get bold pressure less than 130.
Talk about smoking cessation.”
Debora Kamin Mukaz, Assistant Professor of Medicine at Larner College of Medicine at the University of Vermont, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Thrombosis and Haemostasis:
“We published a new paper on long-term mortality and causes of death after venous thromboembolism (VTE) in Journal of Thrombosis and Haemostasis (JTH).
People with any VTE were approximately 3 times more likely to die over 5 years than those without VTE.
The 5-year mortality risk were approximately 6-fold for cancer-provoked VTE and 2-fold for unprovoked and other-provoked VTE.
Those with cancer-provoked VTE were most likely to die of cancer, but circulatory diseases were the main causes of death after all other types of VTE.
This suggests that enhanced cardiovascular prevention in patients with VTE might delay mortality.”
Title: Long-term mortality and causes of death after venous thromboembolism: findings from the Atherosclerosis Risk in Communities Cohort Study
Authors: Debora Kamin Mukaz, Aixin Li, Weihua Guan, Rui Cao, Lingfeng Huo, Weihong Tang, Pamela L Lutsey, Neil A Zakai, Aaron R Folsom, Mary Cushman
Other posts featuring Mary Cushman on Hemostasis Today.
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron
-
Sep 3, 2026, 16:54Ralf Ludwig։ Testing Human-Targeted Therapies in a Human Immune System
-
Sep 3, 2026, 16:35Mohsen Salimi: Non-Contrast Chest CT as a Biomarker for Mild-to-Moderate Anemia
-
Sep 3, 2026, 16:10Tanzeel Alamin Almahdi Gorashi: NLR as an Accessible Biomarker for Monitoring Pediatric Sickle Cell Anemia